Metropolis Healthcare Limited

“Metropolis is a capital-efficient, founder-aligned diagnostics business with a real but regionally bounded moat and a genuine long-term demand runway in underpenetrated India — but it is not exceptional enough to justify ~39x forward earnings when post-COVID margin recovery has stalled, the Hitech acquisition has compressed ROIC, and Dr Lal PathLabs continues to outperform on every metric; base-case 10-year returns of 2–3x (sub-10% CAGR) leave no margin of safety for the risks that matter most: digital aggregator commoditization of routine testing and government price regulation.”